GNRH1 and adenomyosis: A retrospective analysis of 110 adenomyosis patients compared outcomes between two treatment regimens: DNG monotherapy (2 mg/day, n = 40) and sequential therapy combining GnRH agonists (3.6–3.75 mg/day for 3–6 months) followed by DNG (n = 70).